Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: evaluation report

01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer – Bayer
03 - NICE request to the manufacturer for clarification on their submission
04 - Manufacturer clarification response
05 - Consultee submission - AntiCoagulation Europe (ACE)
06 - Consultee submission - British Society of Haemostasis and Thrombosis
07 - Consultee submission - Lifeblood: the thrombosis charity
08 - Consultee submission - Royal College of Nursing
09 - Consultee submission - United Kingdom Clinical Pharmacy Association
10 - Clinical expert personal perspective - Bevan
11 - Clinical expert personal perspective - Crowther
12 - Patient expert personal perspective - Stephens-Boal
13 - Evidence Review Group report prepared by Southampton Health Technology Assessments Centre (SHTAC)
14 - Manufacturer factual accuracy check of Evidence Review Group report
15 - ERG report replacement page 64
16 - ERG report replacement page 67

This page was last updated: 19 April 2013